While NRF2 transient activation is considered to be mostly cytoprotective during the first phases of carcinogenesis, because it limits the DNA damage-induced DNA mutations, sustained NRF2 activation promotes cancer progression and chemoresistance because it counteracts the oxidative stress-induced cell death, particularly in response to therapies [23]. This evidence concerns the gene NFE2L2 and cancer.